

**REMARKS**

The Office Action mailed April 5, 2006, in the nature of a requirement for restriction, has been carefully reviewed. Favorable consideration is respectfully requested.

Restriction has been required among what the Examiner considers to be a plurality of patentably distinct species of the invention, as follows:

Group I, drawn to a DNAzyme that targets the GU cleavage site of nucleotides 198-199 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group II, drawn to a DNAzyme that targets the GU cleavage site of nucleotides 200-201 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group III, drawn to a DNAzyme that targets the GU cleavage site of nucleotides 264-265 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group IV, drawn to a DNAzyme that targets the AU cleavage site of nucleotides 271-272 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group V, drawn to a DNAzyme that targets the AU cleavage site of nucleotides 301-302 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group VI, drawn to a DNAzyme that targets the GU cleavage site of nucleotides 303-304 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group VII, drawn to a DNAzyme that targets the AU cleavage site of nucleotides 316-317 of SEQ ID NO:1, presently comprising claims 20-58 in part;

Group VIII, drawn to a DNAzyme of SEQ ID NO:3, presently comprising claims 20-58 in part;

Group IX, drawn to a DNAzyme of SEQ ID NO: 4, presently comprising claims 20-58 in part;

Group X, drawn to a DNAzyme of SEQ ID NO:5, presently comprising claims 20-58 in part;

Group XI, drawn to a DNAzyme of SEQ ID NO: 6, presently comprising claims 20-58 in part;

Group XII, drawn to a DNAzyme of SEQ ID NO:7, presently comprising claims 20-58 in part;

Group XIII, drawn to a DNAzyme of SEQ ID NO:8, presently comprising claims 20-58 in part;

Group XIV, drawn to a DNAzyme of SEQ ID NO:9, presently comprising claims 20-58 in part;

Group XV, drawn to a DNAzyme of SEQ ID NO:10, presently comprising claims 20-58 in part; and

Group XVI, drawn to an angioplastic stent for inhibition of the onset of restenosis, and methods of use thereof, presently comprising claims 59-62.


Applicant hereby elects Group XI, drawn to the DNAzyme of SEQ ID NO:6. It is respectfully requested that this election should include Group IV as well, as the DNAzyme of SEQ ID NO:6 will cleave SEQ ID NO:1 at the AU cleavage site of nucleotides 271-272.

If the election requirement is maintained, it will be clear on the record that the PTO considers the groups to be patentably distinct from one another *i.e.*, *prima facie* non-obvious from one another. This means that a reference identical to the one group would not render the other group *prima facie* obvious.

Favorable consideration and examination of all pending claims on the merits are respectfully requested.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant

By   
Anne M. Kornbau  
Registration No. 25,884

AMK:srd  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\BN\B\Blaj\atkins1\pto\2006-05-25 Restriction Response.doc